News

February 25, 2021August 24, 2022

Cancer-sniffing Dogs May Help Train Robot Noses to Detect Tumors Early

News

Understanding the molecular components of odors used by trained dogs to detect prostate cancer could help researchers to develop computers with similar diagnostic accuracy, a new study shows. The study, ... Read more

February 23, 2021February 23, 2021

Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT

News

Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can accurately identify which men with intermediate- or high-risk disease will benefit from adding androgen deprivation therapy (ADT) ... Read more

February 18, 2021February 18, 2021

Erleada-Zytiga Combo Delays Progression in mCRPC Patients, Phase 3 Trial Reports

News

Combining Erleada (apalutamide) and Zytiga (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC) significantly extends the time patients live without signs of disease worsening, compared with Zytiga alone, Janssen announced ... Read more

February 16, 2021February 16, 2021

Erleada-ADT Combo Found to Prolong Survival, Delay Cancer Worsening

News

When given in combination with androgen deprivation therapy or ADT, Erleada (apalutamide) significantly prolonged the lives of men with metastatic hormone-sensitive prostate cancer (mHSPC) — without compromising their quality of ... Read more

February 11, 2021February 11, 2021

‘TRUE Love’ Contest Calls for Entries Honoring Caregivers

News

With help from actress Kristen Bell, the Prostate Cancer Foundation (PCF) has opened its 4th annual TRUE Love contest for entries that pay tribute to family members and caregivers of ... Read more

February 10, 2021February 10, 2021

New AI Tool May Better Predict Relapse After Surgery

News

Researchers have developed an artificial intelligence (AI) tool that shows the potential to predict prostate cancer aggressiveness and the likelihood of post-surgery relapse more accurately than standard methods can. Called ... Read more

February 4, 2021February 4, 2021

Dosing Begins in Phase 1 Trial of FT-7051 for Advanced, Resistant Cancer

News

Dosing has begun in a Phase 1 clinical trial testing Forma Therapeutics’ investigational therapy FT-7051 in people with metastatic castration-resistant prostate cancer (mCRPC). Recruiting at sites in Arizona and South Carolina, ... Read more

February 2, 2021February 2, 2021

NBA Teams Join Efforts to Raise Money and Awareness

News

The Prostate Cancer Foundation (PCF) and several NBA teams are joining efforts to raise money and awareness for prostate cancer research throughout February. Various national basketball teams, including the Atlanta ... Read more

January 28, 2021January 28, 2021

Biological Clock Protein CRY-1 Eyed as Therapeutic Target

News

CRY-1, a regulator of our circadian clocks, contributes to disease spread and poor outcomes in prostate cancer patients by boosting DNA repair mechanisms that render cells more resistant to treatments, a ... Read more

January 26, 2021January 26, 2021

EPI-7386 Combo Therapies Enter Trial for Certain mCRPC Patients

News

Essa Pharma has entered a clinical collaboration with Janssen to evaluate its small molecule inhibitor EPI-7386, in combination with either Erleada (apalutamide) or Zytiga (abiraterone acetate) plus prednisone, for patients with ... Read more